1. Home
  2. QXL vs ACRV Comparison

QXL vs ACRV Comparison

Compare QXL & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quantum X Labs Inc. Common Stock

QXL

Quantum X Labs Inc. Common Stock

N/A

Current Price

$5.36

Market Cap

75.6M

Sector

Technology

ML Signal

N/A

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.98

Market Cap

67.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QXL
ACRV
Founded
N/A
2018
Country
Israel
United States
Employees
21
N/A
Industry
Computer Software: Prepackaged Software
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
75.6M
67.2M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
QXL
ACRV
Price
$5.36
$1.98
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$11.67
AVG Volume (30 Days)
114.7K
424.4K
Earning Date
N/A
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
15.13
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$568.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.83
$1.20
52 Week High
$7.70
$3.56

Technical Indicators

Market Signals
Indicator
QXL
ACRV
Relative Strength Index (RSI) 19.72 67.10
Support Level $5.02 $1.62
Resistance Level N/A $2.02
Average True Range (ATR) 0.57 0.12
MACD -0.07 0.04
Stochastic Oscillator 23.96 78.18

Price Performance

Historical Comparison
QXL
ACRV

About QXL Quantum X Labs Inc. Common Stock

Quantum X Labs Inc is an Israel-based multi-disciplinary quantum technology company focused on the research, development, and commercialization of quantum technologies and intellectual property. The company operates across a broad range of domains, including quantum computing, quantum sensing, navigation systems, atomic clocks, and quantum algorithms, with applications spanning defense, aerospace, transportation, cybersecurity, and life sciences.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: